ROSELAND, N.J., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the third quarter ended September 30, 2015, and provided a corporate update.
“During the third quarter, we made great strides in commercializing the Eligen® technology. There were two important developments with our partner, Novo Nordisk A/S (NYSE:NVO). Novo Nordisk announced it will initiate a global phase 3a development program with oral semaglutide, a once daily Type 2 diabetes treatment utilizing SNAC, one of our Eligen technology carriers,” said Alan L. Rubino, President and Chief Executive Officer of Emisphere. “We also entered into an agreement with Novo Nordisk to develop and commercialize oral formulations of certain of Novo Nordisk’s investigational molecules targeting major metabolic disorders, including diabetes and obesity, using our Eligen technology. Novo Nordisk has been an important partner for many years and their continuing development of once daily oral semaglutide and the expanded partnership further validate the Eligen technology’s ability to facilitate absorption from the gastrointestinal tract.”
Hey, check out all the research scientist jobs. Post your resume today!
